The ML-10 molecule is an imaging product which is a molecular tracer, injected into the body with a standard syringe. The tracer binds to cells undergoing apoptosis and is designated for the diagnosis of diseases characterized with apoptosis, or for the assessment of effectiveness of treatment in such diseases. The product was developed by the Company until 2013, and its further development was halted following the results of the Phase II clinical trial for the imaging of apoptosis in brain metastases treated with radiation; results which did not meet the primary endpoints of the trial.
on September 16, 2015, Aposense has signed a Technology Evaluation Agreement with Pfizer, Inc. in connection with the ML-10 molecule which the Company developed as part of its activities in the field of molecular imaging.
The above collaboration is aimed at testing the applicability of the product as a new tool for development of drugs in the field of cancer treatment.